Search
for
Sort by
Research 451–480 of 1000+
- Beyond testosterone cypionate: evidence behind the use of nandrolone in male health and wellness
- Insights into male androgenetic alopecia using comparative transcriptome profiling: hypoxia-inducible factor-1 and Wnt/β-catenin signalling pathways
- Evaluation of Serum Ischemia Modified Albumin Level in Male Patients with Androgenetic Alopecia
- Beyond Minoxidil: Evidence-Based Off-Label Therapies for Male Androgenetic Alopecia
- Effectiveness of Combined Oral Minoxidil and Finasteride in Male Androgenetic Alopecia: A Retrospective Service Evaluation
- ANDROGENINĖS ALOPECIJOS MEDIKAMENTINIO GYDYMO GALIMYBĖS
- Botulinum Toxin Type A Alleviates Androgenetic Alopecia by Inhibiting Apoptosis of Dermal Papilla Cells via Targeting circ_0135062/miR-506-3p/Bax Axis
- Study of Association of Dyslipidemia in Male Androgenetic Alopecia Patients in a Tertiary Care Hospital
- Comparative efficacy of topical finasteride (0.25%) in combination with minoxidil (5%) against 5% minoxidil or 0.25% finasteride alone in male androgenetic alopecia: A pilot, randomized open-label study
- Effect of Skin Type on Efficacy of Laser Treatment for Androgenetic Alopecia: A Review of the Literature
- ANDROGENIC ALOPECIA: PATHOGENETIC MECHANISMS AND THERAPEUTIC APPROACHES
- Differential Diagnosis of Male and Female Pattern Hair Loss
- Evaluating treatments for male androgenetic alopecia: clinical profile and comparative efficacy of platelet rich plasma and minoxidil with finasteride
- [The effect of 1, 25-dihydroxyvitamin D3 on cultured human hair follicle cells from a patients with vitamin D-dependent rickets type II with alopecia].
- Rejuvenation of the Male Brow
- Ischemic Stroke in a Young Adult Male During Finasteride Therapy
- Impact of Reporter Type on Signal Detection of Cancer Therapy-Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
- Impact of Reporter Type on Signal Detection of Cancer Therapy–Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
- Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study
- Evaluation of Serum Ischemia Modified Albumin Level in Male with Androgenic Alopecia
- Combination of adipose-derived stem cell conditioned media and minoxidil for hair regrowth in male androgenetic alopecia: a randomized, double-blind clinical trial
- The use of microneedling associated to photobiomodulation in the treatment of male androgenetic alopecia: Case series
- Abdominal obesity and androgenetic alopecia in male patients of the dermatological profile
- The Impact of the 5α-Reductase Inhibitors (5α-RIs) on Male Sexual Function and Psychological Well-Being
- The Impact of Androgenic Alopecia on the Quality of Life of Male Individuals: A Cross-Sectional Study
- The utilisation of cardiac risk ratio and non-HDL cholesterol markers to assess cardiovascular risk in type 2 diabetes males with lowered serum DHT
- The Use of Neurotoxins in the Male Face
- Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient
- DHT and E2 synthesis-related proteins and receptors expression in male yak skin during different hair follicle stages
- Severe androgenetic alopecia as a proxy of metabolic syndrome in male psoriatic patients older than 59 years